Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Clinical Laserthermia Systems AB publishes half-year report January – June 2022

Summary of the half-year report (relates to the Group) First six months (01/01/2022 – 30/06/2022) · Net sales totalled SEK 1,089,000 (SEK 894,000). · Profit/loss after financial items amounted to SEK -31,818,000 (SEK -32,589,000). · Basic and diluted earnings per share totalled SEK -0.47 (SEK -0.66). · The equity/assets ratio was 0% (54%) on 30 June 2022. Second quarter (01/04/2022 – 30/06/2022) · Net sales totalled SEK 381,000 (SEK 0,000). · Profit/loss after financial items amounted to SEK -17,015,000 (SEK -23,127,000). · Basic and diluted earnings per share

Now we´re moving a city!

After 18 years, it's finally time. LKAB is moving the commercial district from the old city centre to the new one. To mark the occasion, LKAB is holding a three-day inaugural celebration on 1-3 September.In 2004 news of the urban transformation in Kiruna reached the world when it was announced that the city would have to be relocated. This transformation will enable continued mining of Kiirunavaara's rich iron ore, thereby securing jobs and the transition to fossil-free steelmaking. Now the historic day is upon us as Kiruna enters a new era when the new city centre is inaugurated.

Toivo Group Plc strengthens its position in the Leppävaara area in Espoo

Press release, 12 August 2022 at 10:30 a.m.     Toivo Group Plc (hereinafter referred to as “Toivo” or “the Company”) has strengthened its foothold in Leppävaara, Espoo. A legally valid city plan has been granted for the company’s significant new construction project, which enables the implementation of a new apartment building project with more than 80 apartments. Toivo already has 5 projects under way in the Leppävaara area, covering more than 100 apartments.   Leppävaara in Espoo is an important market area for Toivo. Urban development is focused on the area

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 150 - 12 AUGUST 2022  In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Notification of Executive’s transaction with Vestas shares

Vestas Wind Systems A/S, Aarhus, 12 August 2022Company announcement no. 16/2022 In accordance with Article 19 (3) of the EU Market Abuse Regulation, Vestas Wind Systems A/S is required to disclose information regarding trading in Vestas Wind Systems A/S shares and securities by Executives and persons closely associated with an Executive. The statement is based on reports which Vestas Wind Systems A/S has received from one of the Executives, see appendix. Contact detailsVestas Wind Systems A/S, Denmark Mathias Dalsten, Vice PresidentInvestor RelationsTel: +45 2829 5383

Crown Energy: Operator of Joint Venture Block 2B South Africa releases an operations update

Crown Energy AB (publ) is pleased to note today’s Press Release from our operator Eco (Atlantic) oil and gas LTD (“Eco Atlantic”) whereby Eco Atlantic does an operational update on Block 2B South Africa:     According to the press release the Island Innovator rig, owned by Island Drilling Company AS, was released and mobilised today.   The well is expected to spud on 2 September 2022, subject to weather conditions. The well will take approximately 25 days to drill.  The Company plans to seal and plug the well after the test with no remaining equipment left on the sea floor.

Erling Haaland and Viaplay enter multi-market partnership

· Manchester City and Norway striker to star in exclusive Viaplay content · Haaland to become Viaplay ambassador in nine European markets · Viaplay announced partnership with Formula 1 champion Max Verstappen in January Manchester City and Norway’s superstar striker Erling Haaland has agreed a long-term, multi-market partnership with Viaplay. One of the hottest talents in world football, the 22-year-old Haaland will star in an exclusive documentary that gives Viaplay viewers unique insights into both his meteoric career and closely guarded personal life. Haaland will also become a

Bioservo signs an agreement for the sale of Carbonhand[®] with Rehasys in Switzerland

Bioservo Technologies AB has signed a distribution agreement with Rehabilitations Systeme AG for the sale of Carbonhand[®] in Switzerland. The agreement provides access to a new lucrative market and is part of a strong investment in Life Science. Rehasys is one of Switzerland's leading suppliers of technical and medical aids and rehabilitation equipment for people with limited mobility. The company was founded in 1926 and today has a large customer base and caters to health institutions such as rehabilitation clinics, hospitals, nursing homes, doctors' surgeries and orthopedic and

Bioretec Ltd’s Half Year Report 2022 (unaudited): Strong sales growth and RemeOs™ registrations on-going

Bioretec Ltd    Company announcement     12 August 2022 at 9.30 a.m. EETThis is a summary of Bioretec Ltd’s half year report 2022. The complete half year report with tables is attached to this release and available at company web pages at  https://bioretec.com/investors/investors-in-english/releases January-June 2022 in brief · Net sales increased by 35.9% and amounted to EUR 1,422 thousand (1-6/2021: EUR 1,047 thousand). · Sales margin was EUR 1,018 (778) thousand or 71.6% (74.3%) of net sales, up by 30.8%. · Net profit (loss) amounted to EUR -1,367 (-2,791) thousand. Net

Cloudberry Clean Energy ASA | Invitation to presentation of second quarter results 2022

Oslo, Norway, 12 August 2022: Cloudberry Clean Energy ASA (“Cloudberry” or the “Company”) will publish its second quarter results on 18 August 2022 at 07:00 CEST. The company management will host a Q&A session on the same day at 11:00 CEST.Please use the following link to access the live Q&A session: https://tv.streamfabriken.com/cloudberry-clean-energy-asa-q2-2022-presentation 

Indutrade acquires Dutch producer of machine knifes

Indutrade has signed an agreement to acquire all shares in the Dutch company Tebra Messen Industrie B.V., www.tebra.nl, with annual sales of approximately EUR 5 million (SEK 52 million).Tebra is one of the largest producers of machine knives in the Netherlands, serving domestic and international clients with reliable machine knives used in a range of different sectors and industries such as food processing, rubber, recycling, packaging and hygiene. The comprehensive product range, covering stainless steel blades, special knives, rotary die cutters, circular blades and shear blades is

Vitamin D supplementation seems to alleviate depressive symptoms in adults

An extensive meta-analysis suggests that vitamin D supplementation may alleviate depressive symptoms in adults with depression. Conducted by an international team of researchers, the meta-analysis includes dozens of studies from around the world. Depressive symptoms cause a significant disease burden worldwide. The therapeutic efficacy of current antidepressants is often insufficient, which is why further ways to alleviate the symptoms of depression have been sought, for example, from nutritional research. Vitamin D is believed to regulate central nervous system functions the

MPC Container Ships ASA announces date for Q2 and six-month 2022 results

Oslo, 12 August 2022 - MPC Container Ships ASA (the "Company") will be releasing its second quarter 2022 report prior to market opening on Thursday 18 August 2022. The Company will host a webcast for the presentation of the Q2 2022 results commencing on Thursday 18 August 2022 at 15:00 hours CEST / 09:00 hours EDT. The presentation will be made available on the Company’s webpage from 12:00 hours CET / 06:00 hours EDT. There will be a Q&A session after the presentation. The event is being streamed. It is recommended that you listen

Publication of United Bankers Plc’s 2022 Half-Year Financial Report and invitation to result presentation on 26 August 2022

United Bankers Plc Press release 12 August 2022 at 09:00 EEST   Publication of United Bankers Plc’s 2022 Half-Year Financial Report and invitation to result presentation on 26 August 2022   United Bankers Plc will publish its Half-Year Financial Report for the period January-June 2022 on Friday 26 August 2022 at approximately 9.00 am. The Half-Year Financial Report will be available on the company’s website at www.unitedbankers.fi  after publishing. Patrick Anderson, CEO, will present the result to analysts and press at the

Cantargia announces final outcome of the company’s significantly oversubscribed rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.12 August 2022 – The final outcome in Cantargia AB’s (publ) (“Cantargia” or the “Company”

Enhertu approved in US for HER2-mutant NSCLC

12 August 2022 07:00 BST Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo's Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (

Oneflow interim report Q2 2022: New all-time-high in sales

Press releaseAugust 12, 2022 Oneflow publishes its interim report for the second quarter of 2022.April - June 2022 (compared to the same period last year) · Net sales increased 59% to MSEK 16.5 (10.3). Share of Net sales outside Sweden increased to 24% (17) with paying users in 27 countries. · EBIT was MSEK -13.4 (-7.1), with an EBIT margin of -81.3% (-69.1). · Basic earnings per share amounted to SEK -0.58 (-0.39) and diluted to SEK -0.58 (-0.39). · Total ARR increased 66% to MSEK 74.7 (45.1). Net New ARR for the second quarter increased 28% to MSEK 9.0 (7.0). ·

Half-Year Report for the First Half of 2022

April – June 2022     · Net sales totaled SEK 21,093 (19,535) thousand, with a growth rate of 8%. Growth is -4%, adjusted for currency effects. · Gross profit rose by 28% to SEK 22,155 (17,365) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 2,109 (2,793) thousand. · Operating profit declined by SEK 1,129 thousand and totaled SEK 221 (1,350) thousand. · Comprehensive income for the period totaled SEK 811 (1,033) thousand. · Comprehensive income per share totaled SEK 0.01 (0.02). · Cash flow from operating activities was SEK 184 (-1,

CS MEDICA A/S: Publication of interim report Q3

CS MEDICA (”CS MEDICA” or the ”Company”) hereby publishes its interim report for the period October 2021 – June 2022. The report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). Below is a summary of the report.Performance highlights third quarter (April 2022 – June 2022)This year we have invested heavily in preparing our product portfolio for commercial success to reinforce proof-of-content. We were delayed due to COVID-19 with clinical trials, trademarks and our technology platforms CIM/PIM, which are now live. Additionally,

Interim report 1 January – 30 June 2022

Deliveries in Germany under way as per agreement and establishment in the United Kingdom through acquisition in augustSECOND QUARTER 2022 · Net sales increased by 22 percent to MSEK 216 (177). In unchanged currency levels, net sales increased by 19 percent. · Operating profit before amortization of intangible assets (EBITA) decreased by 39 percent to MSEK 11 (18) including negative currency effects of MSEK -3.2 (-0.1). · Cash flow from operating activities amounted to MSEK -13 (15). · Earnings per share amounted to SEK 0.40 (0.70). · During the period, solidity decreased to

Remedy Entertainment's Half-Year Financial Report 2022: Q2 revenue at the previous year's level - increased external development investments burden profitability

Remedy Entertainment Plc | Stock exchange release, August 12, 2022, at 09:00 a.m. (EEST)  Remedy Entertainment Plc | Half-Year Financial Report January–June 2022 Remedy’s Q2 revenue at the previous year’s level – increased external development investments burden profitability Five games in development, including the remake of iconic Max Payne   The Half-Year Financial Report is unaudited. Figures in parenthesis refer to the comparison period in the previous year, unless otherwise stated. HIGHLIGHTS FROM APRIL–JUNE 2022 · Revenue was at the previous year’s level, EUR

Nordic Iron Ore AB prolongs the short-term loan facilities

During 2021 and 2022 Nordic Iron Ore AB has taken up loan facilities of SEK 15.5 million from the Company's three largest owners Bengtssons Tidnings AB, Ludvika Holding AB and Kopparinvest AB as well as the company's board member Timo Lindborg via company. The motivation for the facilities was to provide working capital for evaluating of the Company's financing options. The evaluation on financing options as well as the negotiations with Cargill is progressing and therefore the facilities has now been extended by three months to run through December 2022. Summary of the terms of the

Navamedic ASA: Q2 and first half 2022 financial results

Oslo, 12 August 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, grew revenues by 67.2 percent in Q2 2022 compared to the same period in 2021 to NOK 110.4 million, driven by growth in the company’s key business areas. Navamedic reiterates its mid- to long-term ambition of building a NOK 1 billion company.“We are pleased to report record-high revenues and continued strengthening of our profits and cash flow in the second quarter. This was a result of strong growth across several key  products, particularly

There are no items matching the current filter
There are no more items matching the current filter
Back to top